Since its foundation in 1996 AOP Orphan Pharmaceuticals AG has successfully grown from a single person organization to a fully integrated worldwide acting orphan pharmaceutical company with more than 200 employees (Press release, AOP Orphan Pharmaceuticals, MAY 25, 2018, View Source [SID1234527058]). To prepare for the next stage of growth and expansion it has now been decided to enhance the management capacity through the implementation of a new leadership structure: Executive Board of Directors supported by the Executive Management Team.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

After more than twenty years as CEO of AOP Orphan Pharmaceutical AG, Dr Rudolf Widmann has handed over the CEO function to Mr Andreas Steiner, who has been in his former role as CFO already a board member and instrumental for the development for AOP for the last five years. Dr. Widmann remains a member in the Executive Board with full focus on Research & Development. The Executive Board is completed by Dr Guenther Krumpl, a highly experienced medical and pharmaceutical expert, who will focus on Strategic Corporate Development.

The Executive Management Team is formed by high level professionals, most of them graduated in natural science and have acquired extensive research experience from both university institutions and industry research facilities. This Team takes responsibility for implementation and execution of AOP Orphan ambitious expansion plans.